
Zoetis cleared to acquire Jurox in Australia subject to divestiture
Zoetis acquires Scottish animal health digital tech business
33BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US98978V1035
CUSIP
98978V103
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
12.44
PEG Ratio
1.82
Book Value
7.84
Dividend Share
2.03
Dividend Yield
2.58%
Earnings Share
6.1
Wall Street Target Price
124.59
EPS Estimate Current Year
6.90
EPS Estimate Next Year
7.42
EPS Estimate Current Quarter
1.6154
EPS Estimate Next Quarter
1.8989
Most Recent Quarter
-
Revenue TTM
9,530,999,808
Gross Profit TTM
6,847,000,064
EBITDA
4,073,999,872
Profit Margin
28.04%
Return On Assets TTM
15.53%
Return On Equity TTM
67.75%
Revenue Per Share TTM
21.807
Qtly Revenue Growth YOY
2.90%
Diluted Eps TTM
6.1
Qtly Earnings Growth YOY
6.00%
Trailing PE
12.44
Forward PE
11
Price Sales TTM
3.3381
Price Book MRQ
9.8408
Enterprise Value Revenue
4
Enterprise Value EBITDA
9
162.76
4.53%45.00
3.64%31.85
3.11%87.43
2.32%9.27
0.38%13.60
0.00%30.19
0.00%216.85
-2.21%33.68
-1.32%15.65
-0.54%Curated watchlists where ZTS is featured.